Literature DB >> 18925623

Prospective experience with integrated prenatal screening and first trimester combined screening for trisomy 21 in a large Canadian urban center.

Nanette Okun1, Anne M Summers, Barry Hoffman, Tianhua Huang, Elizabeth Winsor, David Chitayat, A Staines, Jo-Ann Johnson.   

Abstract

OBJECTIVES: To evaluate the performance of integrated prenatal screening (IPS) and first trimester combined screening (FTS) for trisomy 21 in a large Canadian urban center.
METHOD: Prospective data collection on women having FTS at one center from 1 November 2003 to 31 December 2005, or IPS at another from 1 January 2003 to 31 December 2005. A positive screen was defined as adjusted risk for trisomy 21 >or= 1/200 at term or nuchal translucency >or= 3.5 mm.
RESULTS: 32 227 and 14 487 women were screened in the IPS and FTS programs, respectively. Detection rates (DRs) and positive rates (PRs) for trisomy 21 were 88.4% (95% CI: 81.6-91.5) and 3.3% (95% CI: 3.1-3.5) for IPS, and 83.9% (95% CI: 74.7-93.0) and 4.0% (95% CI: 3.7-4.3) for FTS. DR adjusted for viability bias was 85.2% for IPS and 78.6% for FTS. Applying both the screens to the 78 134 women who submitted prenatal screens in Ontario in 2005, thereby eliminating the effect of differences in the distribution of maternal age between screens, gave a DR (corrected for viability bias) and PR of 81 and 3.1% for IPS, and 76 and 3.4% for FTS.
CONCLUSIONS: Both IPS and FTS perform well and are feasible in a practical clinical setting.

Entities:  

Mesh:

Year:  2008        PMID: 18925623     DOI: 10.1002/pd.2084

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  7 in total

1.  Rates of prenatal screening across health care regions in Ontario, Canada: a retrospective cohort study.

Authors:  Robin Z Hayeems; Michael Campitelli; Xiaomu Ma; Tianhua Huang; Mark Walker; Astrid Guttmann
Journal:  CMAJ Open       Date:  2015-04-02

Review 2.  Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women.

Authors:  Mylène Badeau; Carmen Lindsay; Jonatan Blais; Leon Nshimyumukiza; Yemisi Takwoingi; Sylvie Langlois; France Légaré; Yves Giguère; Alexis F Turgeon; William Witteman; François Rousseau
Journal:  Cochrane Database Syst Rev       Date:  2017-11-10

Review 3.  First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2017-03-15

Review 4.  First and second trimester serum tests with and without first trimester ultrasound tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2017-03-15

5.  Prospective experience with contingent screening strategy for Down syndrome in Estonia.

Authors:  Kai Muru; Mari Sitska; Karin Asser; Aivar Ehrenberg; Helle Karro; Katrin Ounap; Tiia Reimand
Journal:  J Community Genet       Date:  2010-10-02

6.  Trends in the use of prenatal testing services for fetal aneuploidy in Ontario: a descriptive study.

Authors:  Tianhua Huang; Shelley Dougan; Mark Walker; Christine M Armour; Nan Okun
Journal:  CMAJ Open       Date:  2018-10-05

7.  The consequences of implementing non-invasive prenatal testing with cell-free foetal DNA for the detection of Down syndrome in the Spanish National Health Service: a cost-effectiveness analysis.

Authors:  J C Bayón; E Orruño; M I Portillo; J Asua
Journal:  Cost Eff Resour Alloc       Date:  2019-03-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.